Committee on Energy and Commerce
U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Richard Hatchett		
2. Your Title: Director (Acting)		
3. The Entity(ies) You are Representing: HHS/ASPR/BARDA		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	**Yes** X	**No**
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signatu [redacted] **Date:** 5/18/16

Richard J. Hatchett, MD

[redacted]

PROFESSIONAL EXPERIENCE

A. Professional Experience

(Acting) Director **03/2016-Present** ***Biomedical Advanced Research and Development Authority***
(Acting) Deputy Assistant Secretary for Preparedness and Response ***U.S. Department of Health and Human Services***

Chief Medical Officer & Deputy Director **01/2015-03/2016**

Chief Medical Officer & Deputy Director for Strategic Sciences and Management **01/2011-01/2015**

Duties: *Position supports the Assistant Secretary for Preparedness and Response. Provides scientific and strategic direction on a ~$1 billion a year program ($1.204 billion in FY2015, due to Ebola Supplemental funding) with over 160 active development projects. Provides leadership, oversight and support to BARDA's eight division directors, Matrix Team leads, and ~160 staff. In this role, manages a broad Research and Development (R&D) portfolio of medical countermeasures against chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. Assists the Director with annual and multiyear budget formulation and execution. Represents BARDA in matters of policy, procurement, and the management of BARDA-sponsored research involving human subjects. Serves as Milestone Decision Authority on selected projects and subject matter expert on radiological and nuclear countermeasures. Facilitates collaboration on medical countermeasure development, procurement, and deployment efforts with key partners including industry, other government agencies, non-governmental organizations, and international partners, including the World Health Organization (WHO). Responsible for reviewing and approving all external BARDA publications (scientific articles, abstracts, public presentations, press releases, blogposts, etc.). As Deputy Director for Strategic Sciences and Management, primary responsibilities included oversight of programs relating to strategic science and innovation, strategic affairs and reporting, the development of science and preparedness policy, human resources, communications, and organizational marketing. For BARDA, the ultimate outcome is for candidate vaccines, therapeutics, diagnostics and medical devices to achieve U.S. Food and Drug Administration (FDA) licensure, approval, or clearance. Fourteen (14) products supported by BARDA have achieved this milestone since 2011, twenty-three (23) altogether since BARDA was established in 2006. In recent years, BARDA has also been called upon to respond to national emergencies, most notably the 2009-H1N1 pandemic, during which 6 supported products received licensure or clearance, the Ebola epidemic in West Africa, during which BARDA support advanced or accelerated the development of 12 products, five of which entered human clinical trials in West Africa, and the current Zika epidemic.*

Director for Medical Preparedness Policy **04/2009-01/2011** ***White House National Security Staff***
Executive Office of the President

Duties: *Detailed by name request to assist the Resilience Directorate and Deputy Homeland Security Advisor in coordinating the national response to the 2009-H1N1 pandemic. Provided subject matter expertise, strategic advice, and policy guidance to the Homeland Security Advisor, Deputy Homeland Security Advisor, and other White House principals on matters related to pandemic response, including surveillance, border control, vaccine development and procurement, the national vaccination program, monitoring for vaccine adverse events, the role of antiviral medications and nonpharmaceutical interventions, the protection of high-risk populations, and epidemic analysis and forecasting. Served as co-chair of the 2009-H1N1 Sub-Interagency Policy Committee, which coordinated domestic policies related to the pandemic, and the International 2009-H1N1 Vaccine Assistance Sub-Interagency Policy Committee, which developed the proposal, enacted by the President, to donate 10% of the U.S. vaccine supply to WHO for use in developing nations. In September 2009, nine nations, led by the United States, pledged to donate vaccine to developing countries, and WHO ultimately delivered over 78 million vaccine doses to a total of 77 countries, with recipients in each of the six WHO regions. In the post-pandemic period, established and chaired an International Health Regulations Working Group and an Emerging Pandemic Threats Sub-Interagency Policy Committee that were subsequently absorbed into the Administration's Global Health Security Agenda initiative. Instigated and played a leading role in conceptualizing the 2010 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Review, which resulted in administrative reforms within the PHEMCE and the establishment of the Centers for Innovation in Advanced Development and Manufacturing and Fill-Finish Manufacturing Network by BARDA, the Medical Countermeasures Initiative*

(MCMi) at FDA, and the Concept Acceleration Program at the National Institutes of Allergy and Infectious Diseases (NIAID). The PHEMCE Review is viewed as a watershed event in the history of the civilian medical countermeasures program.

Director for Biodefense **11/2005-05/2006** ***White House Homeland Security Council***
Executive Office of the President

Duties: *Detailed by name request to assist the Special Assistant to the President and Senior Director for Biodefense in drafting the National Strategy for Pandemic Influenza Implementation Plan, which continues to provide the framework for national pandemic preparedness efforts. Devised the structure for the Implementation Plan, served as principal author of the "Protecting Human Health" chapter, and helped set national policy on international containment and border strategies. Devised national community containment strategy and coordinated interagency modeling effort to test this strategy. Performed historical analysis, published in the* Proceedings of the National Academy of Science *and featured in the* New York Times *and* The Atlantic, *that provided strong evidence of the efficacy of nonpharmaceutical interventions during the 1918 pandemic. This initially highly controversial strategy became the basis for the U.S. Centers for Disease Control and Prevention (CDC)'s* Interim Pre-pandemic Planning Guidance: Community Strategy for Pandemic Influenza Mitigation in the United States: Early, Targeted, Layered Use of Nonpharmaceutical Interventions *and was successfully implemented, with anticipated reductions in disease transmission and epidemic propagation, in Mexico City at the beginning of the 2009-H1N1 pandemic.*

Associate Director for Radiation Countermeasures Research and Emergency Preparedness **07/2005-01/2011** ***Division of Allergy, Immunology and Transplantation***
National Institute for Allergy and Infectious Diseases
U.S. National Institutes for Health

Duties: *Responsible for scientific and strategic direction, administration, and financial management ($46-61 million a year) of NIAID's extramural Radiation Countermeasures Research and Development Program. Scientific goals of the program were to understand the effects of different levels of radiation exposure; define the mechanisms of radiation injury, including secondary responses and multisystem injury; determine mechanisms of protection, mitigation, and treatment; identify and characterize animal models relevant to human responses; identify new drug candidates; and accelerate the transition from candidate to product. Supervised a staff of seven (six Ph.D.s). Established eight academic Centers for Medical Countermeasures against Radiation (CMCRs) and the Medical Countermeasures against Radiological and Nuclear Threats (MCART) product development consortium, a multi-institutional, academic contract research organization composed of 15 different research, development, regulatory, and administrative entities from the United States, Canada, and England and led by the University of Maryland. Developed an innovative and highly successful non-contractual business model providing private sector partners with access to the resources, services, and expertise required for the research, discovery, and development of radiation/nuclear medical countermeasures. Met with approximately 130 companies and arranged screening of ~40 compounds in rodent models of the hematopoietic acute radiation syndrome (ARS), 8 compounds for gastrointestinal ARS, and 4 compounds for efficacy in decorporating various radionuclides including americium-241 and plutonium-239. Oversaw the design and performance by MCART of a pivotal GLP study of granulocyte colony stimulating factor (G-CSF; Neupogen) in rhesus macaques that demonstrated a significant survival benefit for treated animals and resulted in Neupogen's approval by FDA for the treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident (the first radiation countermeasure approved under the FDA "Animal Rule"). At least 26 investigators, groups, or companies that received critical seed funding or other support from the program have gone on to receive funding from BARDA for further development of specific products. Coordinated NIAID activities with those of BARDA, the National Cancer Institute, the Departments of Defense and Energy, and the National Aeronautics and Space Administration. Fostered international exchanges and collaborations with WHO as well as French, Indian, Japanese, Korean, and Russian scientists.*

Senior Medical Advisor **06/2002-06/2004** ***Office of Public Health Preparedness (subsequently the Office of the Assistant Secretary for Public Health Emergency Preparedness)***
U.S. Department of Health and Human Services

Duties: *Position supported the Director of the Office of Public Health Preparedness and subsequently the Acting Assistant Secretary for Public Health Emergency Preparedness. Served as medical advisor, subject matter expert, and action officer on emergency preparedness and response issues ranging from weather-related emergencies to emerging infectious diseases to CBRN terrorism. Represented the Director and Acting Assistant Secretary on a number of White House Homeland Security Council working groups. For OSTP, coordinated review of existing and promising radiological countermeasures, the development of a radiobiology research and development agenda, and an analysis of national biodosimetry capability requirements. Work products led to establishment of NIAID Radiation Countermeasures Research Program. Served as Co-Chair of Department of Homeland Security Working Group on Radiological Dispersal and Improvised Nuclear Devices that developed medical and operational response guidance for clinicians and first responders. Developed original proposal for employing U.S. Postal Service personnel to deliver contents of Strategic National Stockpile, which was adopted by U.S. Department of Health and Human Services, the U.S. Postal Service and the U.S. Department of Homeland Security and*

incorporated into the Cities Readiness Initiative. Participated in comprehensive nine-month review of the roles and missions of the Department of Defense in homeland security. Coordinated HHS participation (OPHP, FDA, CDC, HRSA, SAMHSA, IHS, USPHS, and the Office of Public Affairs) in the TOPOFF 2 National Combating Terrorism exercise. Organized internal after-action review for TOPOFF2 and coordinated Departmental input to interagency after-action process. Assisted the Office of the Surgeon General with the establishment of the Medical Reserve Corps program. Worked with HRSA, NIST, JCAHO, AHA, AMA, FSMB, National Council of State Boards of Nursing, and others to develop specifications for an Emergency System for the Advanced Registration of Volunteer Healthcare Professionals (ESAR-VHP). Work products articulated critical benchmarks for credentialing and resulted in establishment of the national ESAR-VHP program, now operative in 50 states. Led Secretary's Emergency Response Team deployed to North Carolina during and after Hurricane Isabel. Served in the HHS Secretary's Operations Center during the response to the Severe Acute Respiratory Syndrome (SARS).

Clinical Assistant Physician **07/2001-06/2003** ***Department of Medicine***
Instructor **07/1998-06/2001** ***Memorial Sloan-Kettering Cancer Center***

Duties: *One of six clinicians staffing the Urgent Care Center, providing emergency care to patients receiving treatment at Memorial Sloan-Kettering Cancer Center. Patients, most of whom were on clinical protocols, presented with common oncologic emergencies including neutropenic fever and sepsis, spinal cord compression, deep venous thrombosis, pulmonary embolism, drug reactions, nausea/vomiting/diarrhea, dehydration, electrolyte abnormalities, ascites, pleural effusions, changes in mental status, &c. Worked seven 12-hour shifts every two weeks. Patient load, shared between two day-shift and one night-shift physicians, averaged between 50-70 patients a day. Supervised a staff of 4-6 nurses and 2 administrative assistants per shift, providing overall plan for care and determining dispositions (in consultation with each patient's attending physician) for patients admitted to the Urgent Care Center. In a volunteer capacity, served as coordinator of main volunteer medical triage facility at Ground Zero from September 12, 2001 till September 14, 2001. Organized a 30-bed treatment and counseling facility, managing approximately 250 professional volunteers. Subsequently developed original proposal for Civilian Medical Reserve, which was adopted by U.S. Department of Health and Human Services and the President (who referred to the initiative in the 2002 State of the Union address) in creating the Medical Reserve Corps under the direction of the U.S. Surgeon General. The MRC currently has 997 units nationwide with more than 200,000 registered volunteers.*

Coordinator of Clinical Activities **08/1997-11/1997** ***Yale University Ebola Project (Makokou, Gabon)***

Duties: *Served under the Principal Investigator, Dr. Robert W. Ryder, as clinical coordinator during a post-outbreak serosurvey and census of eight villages on the upper Ivindo River. Was responsible for performing census and GPS mapping of each village, organizing and conducting medical clinics, collecting and processing of serum specimens from study participants, record keeping and labeling of specimens, maintaining the cold chain, shipping of specimens to the National Institute for Communicable Diseases in South Africa, project financial management, and a staff of five. Cultivated close working relationship with local officials in Makokou and with the Gabonese Ministry of Health, Social Welfare, and National Solidarity.*

Research Fellow **07/1992-06/1993** ***Department of Pharmacology***
Copernicus Academy of Medicine (Kraków, Poland)

Duties: *Worked in the laboratory of Dr. Ryszard J. Gryglewski, Professor and Chairman of Pharmacology, between my second and third years of medical school. Research focused on identifying and characterizing the mechanism of action of agonists and antagonists of endothelial nitric oxide synthase. Contributed to the characterization of a novel class of nitric oxide synthase inhibitors whose lead compound, ebselen, is a glutathione peroxidase mimic. Performed routine laboratory tasks including preparation and mounting of endothelium-intact and denuded rabbit aorta rings, enzymatic reduction of bovine endothelium, porcine cerebellum, and murine spleen, radioimmunoassay of cGMP, measurement of arginine conversion to nitric oxide, plotting of results, and analysis of data.*

Research Assistant **06/1991-08/1991** ***Department of Cardiac Medicine***
08/1989-03/1990 ***National Heart and Lung Institute***
Imperial College London

Duties: *Worked in the laboratory of Dr. Peter H. Sugden, Professor of Cardiac Medicine, in the academic year prior to and summer following my first year of medical school. Research focused on elucidating the mechanisms of anabolic physiology by quantification of protein synthesis in anterogradely perfused rat hearts and isolated cardiomyocytes in the presence of (a) adrenaline and selective modulators of α- and β-adrenergic receptors; and (b) endothelin-1 and its analogues. Results suggested that the stimulation of protein synthesis was dependent on the stimulation of phosphoinositide hydrolysis via a protein kinase C-mediated increase in intracellular pH. Performed routine laboratory tasks including sacrifice of animals, preparation of rat hearts for perfusion and ventricular myocytes by collagenase digestion, prelabeling and resuspension of myocytes, measurement of rates of protein synthesis, and plotting of results.*

B. Miscellaneous Professional Service

Member	**11/2015-Present**	**NIAID Centers for Medical Countermeasures against Radiation Consortium External Advisory Committee**
Member	**09/2014-Present**	**Los Alamos National Laboratory Integrative Biosurveillance Advisory Committee**
Member	**08/2013-Present**	**National Biodefense Science Board Selection Committee**
Member	**02/2010-04/2010**	**AAAS Health, Education, and Human Welfare Fellowship Selection Committee**
WHO Consultant	**03/2009**	**WHO Consultation on Harmonization of Medical Countermeasures: Acute Radiation Syndrome/Multiple-Organ Dysfunction Management**
Member	**01/2008-05/2008**	**Epidemiologist and Medical Physicist Search Committee, Radiation Epidemiology Branch, National Cancer Institute**
Participant/Coordinator	**08/2005-10/2005**	**Federal Medical Response to Hurricanes Katrina and Rita, Detail to the Office of Public Health Emergency Preparedness**
Coordinator	**12/2004**	**Interorganizational Meeting on Radiological/Nuclear Mass Casualty Preparedness**
Consultant	**12/2002-1/2003**	**International Associations of Fire Chiefs "Fire Chief's Guide to Smallpox Vaccination"**
HHS Program Coordinator	**11/2002-05/2003**	**TOPOFF2 National Combating Terrorism Exercise**

C. Volunteer & Civic Experience

Vice President	**12/1998-Present**	**Hatchett Foundation**
Deacon	**01/2008-Present**	**Bradley Hills Presbyterian Church**
Moderator	**01/2010-12/2010**	
Vice-Moderator	**01/2008-12/2009**	
Timer	**09/2013-Present**	**All-Star Aquatics Swim Club**
Timer	**06/2013-Present**	**Seven Locks Swim Club**

EDUCATION & POSTDOCTORAL TRAINING

2013
Leadership for a Democratic Society Executive Training
Federal Executive Institute, Charlottesville, VA

2003-2005
Medical Oncology Fellowship
Duke University Medical Center

1995-98
Medical Internship and Residency
New York Hospital – Cornell Medical Center (now known as New York Presbyterian Hospital)
Memorial Sloan-Kettering Cancer Center

1990-95
Doctor of Medicine (MD)
Vanderbilt University, School of Medicine

1985-89
Bachelor of Arts (BA) *summa cum laude*
Vanderbilt University, College of Arts and Sciences

LICENSES & CERTIFICATION

ABIM – Internal Medicine	**08/1998-12/2008**	**Diplomate Number 187768**
ABIM – Medical Oncology	**11/2005-Present**	**Diplomate Number 187768**

PROFESSIONAL ACTIVITIES

Society Membership

1. Member, American Society of Clinical Oncology, 2004-Present
2. Member, American Society of Hematology, 2004-Present

Leadership/Chairmanship

1. Institute of Medicine Planning Committee for Workshop on Enabling Rapid Response and Sustained Capability with Medical Countermeasures to Mitigate Risk of Emerging Infectious Diseases, 2014-2015.
2. HHS Medical Countermeasures Strategic Investor Acquisitions Team, 2012-2013.
3. HHS Novel and Emerging Threats Working Group, 2011-2012.
4. National Security Staff International Health Regulations Working Group, 2010-2011.
5. National Security Staff Emerging Pandemic Threats Sub-Interagency Policy Committee, 2010-2011.
6. National Security Staff International 2009-H1N1 Vaccine Assistance Sub-Interagency Policy Committee, 2009-2010.
7. National Security Staff 2009-H1N1 Sub-Interagency Policy Committee, 2009-2011.
8. HHS Public Health Emergency Medical Countermeasures Enterprise Radiological / Nuclear Threat Countermeasures Requirements Working Group, 2006-2009.
9. Weapons of Mass Destruction Medical Countermeasures Steeering and Integration Group Radiological / Nuclear Threat Countermeasures Committee, 2006.
10. Weapons of Mass Destruction Medical Countermeasures Steeering and Integration Group Product Development Tools ad hoc Radiological / Nuclear Threat Countermeasures Subcommittee, 2006-2007.
11. Homeland Security Council Pandemic Influenza Community Mitigation Modeling Initiative, 2006.
12. Office of Science and Technology Policy Radiological / Nuclear Threat Countermeasures Working Group, 2003-2004.
13. Emergency Preparedness and Response Subpanel, 2003 Defense Science Board Summer Study on the Role of the Department of Defense in Homeland Security, 2002-2003.
14. Medical Preparedness and Response Subcommittee of the Office of Homeland Security Radiological Dispersion Device / Nuclear Smuggling Working Group, 2002-2003.
15. HHS Emergency Credentialing Working Group, 2002-2003.
16. Civilian Medical Reserve Working Group, 2001-2002.

Committee/Panel Memberships

1. Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (*ex officio*), 2015-present.
2. World Health Organization Advisory Committee on Variola Virus Research, 2012-present.
3. National Biodefense Science Board Selection Committee, 2011-present.
4. Public Health Emergency Medical Countermeasures Enterprise Executive Committee, 2011-present
5. Global Health Initiative Interagency Policy Committee, 2010-2011.
6. International Bioengagement Working Group, 2010-2011.
7. National Security Staff World Health Organization Sub-Interagency Policy Committee, 2010-2011.
8. National Security Staff Innovative Financing Sub-Interagency Policy Committee, 2010-2011.
9. Center for Strategic and International Studies Working Group on Department of Defense Overseas Labs, 2010-2011.
10. Department of State Pandemic Influenza Preparedness Open-Ended Working Group, 2010-2011.
11. NIH Representative (representing the Director, NIH), National Science and Technology Council Committee on Homeland and National Security, 2008-2009.
12. Institute of Medicine Committee on Preparedness of Major Metropolitan Areas for a Nuclear Event, 2008-2009.

13. NIAID Representative, Pandemic and All Hazards Preparedness Act National Health Security Strategy Working Group, 2007-2009
14. National Biodefense Science Board Medical Countermeasure Markets and Sustainability Working Group, 2007-2009.
15. Biodefense Advanced Research and Development Authority Radiological/ Nuclear Subgroup on Consequence Management, 2007-2009.
16. Global Health Security Initiative Radiological / Nuclear Threat Working Group, 2007-2009.
17. NIAID Representative, Public Health Emergency Medical Countermeasures Radiological / Nuclear Integrated Program Team. 2007-2011.
18. NIAID Alternate, Institute of Medicine Forum on Medical and Public Health Preparedness, 2007-2011.
19. NIAID Representative, Pandemic and All Hazards Preparedness Act National Health Security Strategy Working Group, 2007-2009.
20. NIAID Alternate, Public Health Emergency Medical Countermeasures Enterprise Governance Board Executive Committee, 2007-2011.
21. Board of Advisors, International Consortium for Applied Radiation Research, 2007-2008.
22. Radiation Injury Treatment Network Steering Committee, 2006-2011.
23. NIAID Representative, Radiological / Nuclear Threat Risk Management Group, 2006-2007.
24. Administration for Healthcare Research and Quality Call Center Advisory Panel, 2006.
25. Homeland Security Council National Strategy for Pandemic Influenza Implementation Plan Writing Team, 2005-2006.
26. Weapons of Mass Destruction Medical Countermeasures Steering and Integration Group Threat Prioritization Working Group, 2005.
27. National Marrow Donor Program / American Society for Blood and Marrow Transplantation Transplant Contingency Response Planning Committee, 2005.
28. Duke University Radiation Countermeasures Center of Research Excellence Planning Committee, 2004.
29. HHS Representative, Homeland Security Council Credentialing Working Group, 2004.
30. HHS Representative, Homeland Security Council Scenarios Working Group, 2003-2004.
31. HHS Representative, Homeland Security Council Nuclear / Radiological Strategy Review Group, 2003.
32. Member, National Cooperative Highway Research Program Project Panel SP20-59(19) "Transportation Response Options: Scenarios of Infectious Disease, Biological Agents, Chemical, Biological, Radiological, or Nuclear Exposure", 2003-2004.
33. Homeland Security Council Genetically Modified and Novel Pathogens Working Group, 2003.
34. Veterans Health Affairs Emergency Management Strategic Healthcare Group Technical Advisory Committee, 2003-2004.
35. HHS Spokesperson, TopOff 2 After Action Review Review Panel, 2003.
36. HHS Representative, Federal Radiological Preparedness Coordinating Committee, 2003-2004.
37. Office of Science and Technology Policy Weapons of Mass Destruction Medical Countermeasures Working Group (2003-2004)Member, IEEE Medical Technology Policy Committee Bioterrorism Working Group, 2002.
38. Participant, Greater New York Hospital Association Emergency Preparedness Coordinating Council, 2002.

EDITORIAL ACTIVITIES

1. *Guest Editor,* Disaster Medicine and Public Health Preparedness, 2011.

Peer Reviewer

1. Biosecurity and Bioterrorism (now Health Security)
2. Clinical Trials
3. Disaster Medicine and Public Health Preparedness
4. Emerging Infectious Diseases
5. Health Physics
6. JAMA
7. Journal of Medical Ethics
8. Journal of Theoretical Biology
9. PLoS Medicine
10. Radiation Measurements
11. Radiation Research

Editorial Advisory Board Membership

1. Bioterror Medical Alert

HONORS AND AWARDS

2015	BARDA Service Award for outstanding achievement and dedication in promoting the development of Ebola medical countermeasures during the 2014-2015 Ebola response
2015	Duke Talent Identification Program Distinguished Alumnus Award
2014	NIAID Merit Award, for leadership in developing G-CSF as a radiation countermeasure
2012	Bayside Academy Academic and Professional Society Distinguished Alumnus
2010	Letter of commendation from John O. Brennan, Assistant to the President for Homeland Security and Counterterrorism, for "superb work on the 2009 H1N1 flu."
2010	Certificate of appreciation from the Executive Office of the President for "exceptional service in facilitating the overall policy direction and coordination regarding national 2009-H1N1 influenza pandemic preparedness and response."
2010	National Security Medallion for service during the 2009-H1N1 pandemic
2009	HHS Certificate of Appreciation for exemplary leadership, commitment, and effectiveness as a founder of the Radiation Injury Treatment Network
2008	NIH Office of the Director Merit Award, for leadership and service in the development of the HHS Implementation Plan for the Pandemic and All Hazards Preparedness Act
2008	NIAID Merit Award, in recognition of outstanding efforts to ensure a fully integrated advanced biological product development research program
2007	NIAID Merit Award, in recognition of outstanding contributions and efforts in support of the NIAID mission
2006	NIAID Merit Award, in recognition of outstanding contributions and efforts in support of the NIAID mission
2006	HHS Secretary's Award for Distinguished Service during the Hurricane Katrina response
2006	NIH Director's Award for designing and implementing a robust program to develop medical countermeasures against radiological and nuclear terrorist attack
2001	Bioterrorism Officer Grant, Alfred P. Sloan Foundation, to support activity of Civilian Medical Reserve Working Group
1997	Barbara Hrbek Zucker Traveling Fellowship in Clinical Infectious Diseases
1995	Oscar Crofford Award for Excellence in Scientific Research, Vanderbilt University
1992	American Heart Association Student Research Fellowship
1992	AΩA Student Essay Contest, 1st Place
1991	AΩA Student Essay Contest, Honorable Mention
1990	Justin Potter Scholarship, Vanderbilt University School of Medicine
1989	Summa Cum Laude Graduate, Vanderbilt University
1989	Kathryn Irene Glascock Intercollegiate Poetry Contest, 2nd Place
1985	Harold Stirling Vanderbilt Scholar, Vanderbilt University

PUBLICATIONS

Journal Articles Peer Reviewed

1. DiCarlo AL, Kaminski JM, **Hatchett RJ,** Maidment BW. Role of thrombocytopenia in radiation-induced mortality and review of therapeutic approaches targeting platelet regeneration after radiation exposure. *Journal of Radiation Oncology* 2015;5:19-32.
2. Rainisch G, Asher J, George D, Clay M, Smith TL, Kosmos C, Shankar M, Washington ML, Gambhir M, Atkins C, **Hatchett R,** Lant T, Meltzer MI. Estimating Ebola Treatment Needs, United States. *Emerging Infectious Diseases* 2015;21:1273-1275.
3. Coleman CN, Sullican JM, Bader JL, Murrain-Hill P, Koerner JF, Garrett AL, Weinstock DM, Case C Jr, Hrdina C, Adams SA, Whitcomb RC, Graeden E, Shankman R, Lant T, Maidment BW, **Hatchett R.** Public health and medical preparedness for a nuclear detonation: the nuclear incident medical enterprise. *Health Physics* 2015;108:149-160.
4. Smith K, Jarris PE, Inglesby T, **Hatchett R,** Kellermann AL. Public health preparedness research. *Journal of Public Health Management and Practice* 2013;19 Suppl 2:S6-8.

5. Coleman CN, Adams S, Adrianopoli C, Ansari A, Bader JL, Buddemeier B, Caro JJ, Casagrande R, Case C Jr, Caspary K, Chang AS, Chang HF, Chao N, Cliffer KD, Confer D, Deitchman S, Derenzo EG, Dobbs A, Dodgen D, Donnelly EH, Gorman S, Grace MB, **Hatchett R,** Hick JL, Hrdina C, Jones R, Kane E, Knebel A, Koerner JF, Laffan AM, Larson L, Livinski A, Mackinney J, Maidment BW, Manning R, Marinissen MJ, Martin C, Michael G, Murrain-Hill P, Nemhauser JB, Norwood AE, Nystrom S, Raheem M, Redlener I, Sheehan K, Simon SL, Taylor TP, Toner E, Wallace KS, Wieder J, Weinstock DM, Wiley AL Jr, Yeskey K, Miller CW, Whitcomb RC Jr. Medical planning and response for a nuclear detonation: a practical guide. *Biosecurity and Bioterrorism* 2012;10:346-371.
6. Coleman CN, Hrdina C, Casagrande R, Cliffer KD, Mansoura MK, Nystrom S, **Hatchett R,** Caro JJ, Knebel AR, Wallace KS, Adams SA. User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents. *Disaster Medicine and Public Health Preparedness* 2012;6:408-414.
7. **Hatchett RJ**. Slow progress in preparing for radiological and nuclear emergencies. *Disaster Medicine and Public Health Preparedness* 2011;5:180-182.
8. **Hatchett R,** Coleman CN, Lurie N. Health risks of accidents at nuclear power plants. *New England Journal of Medicine* 2011;365:963-964.
9. Ross JR, Case C, Confer D, Weisdorf DJ, Weinstock D, Krawisz R, Chute J, Wilhauk J, Navarro W, Hartzman R, Coleman CN, **Hatchett R,** Chao N. Radiation Injury Treatment Network (RITN): healthcare professionals preparing for a mass casualty radiological or nuclear incident. *International Journal of Radiation Biology* 2011;87:748-753.
10. Grace MB, Cliffer KD, Moyer BR, Coleman CN, Prasher JM, **Hatchett R**, Mercier J, Manning RG, Bader JL, Disbrow GL, Kovacs GR. The U.S. Governmenr's medical countermeasure portfolio management for nuclear and radiological emergencies: synergy from interagency cooperation. *Health Physics* 2011;101:238-247.
11. Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC, **2009 H1N1 Surveillance Group**. Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. *Biosecurity and Bioterrorism* 2011;9:89-115.
12. Glasser JW, Hupert N, McCauleyMM, **Hatchett R.** Modeling and public health emergency responses: lessons from SARS. *Epidemics* 2011;3:32-37.
13. Hafer N, Maidment B, **Hatchett R.** The NIAID Radiation Countermeasures Program business model. *Biosecurity and Bioterrorism* 2010;8:357-363.
14. DiCarlo AL, Ramakrishnan N, **Hatchett RJ**. Radiation combined injury: overview of NIAID research. *Health Physics* 2010;98:863-867.
15. Hafer N, Cassatt D. DiCarlo A, Ramakrishnan N, Kaminski J, Norman MK, Maidment B, **Hatchett R.** NIAID/NIH Radiation/Nuclear Medical Countermeasures Product Research and Development Program. *Health Physics* 2010;98:903-905.
16. Grace MB, Moyer BR, Prasher J, Cliffer KD, Ramakrishnan N, Kaminski J, Coleman CN, Manning RG, Maidment BW, **Hatchett R.** Rapid radiation dose assessment for radiological public health emergencies: roles of NIAID and BARDA. *Health Physics* 2010;98:172-178.
17. Cassatt DR. Kaminski JM, **Hatchett RJ,** DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Report of an NIAID workshop, September 17-18, 2007. *Radiation Research* 2008;170:540-548.
18. Weinstock DM, Case C, Bader J, Chao NJ, Coleman N, **Hatchett R,** Weisdorf D, Confer D. Radiological and nuclear events: contingency planning for hematologist/oncologists. *Blood* 2008;111:5440-5445.
19. DiCarlo AL, **Hatchett RJ**, Kaminski JM, Ledney GD, Pellmar TC, Okunieff P, Ramakrishnan N. Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. Report of an NIAID workshop, March 26-27, 2007. *Radiation Research* 2008;169:712-721.
20. **Hatchett RJ,** Mecher CE, Lipsitch M. Public health interventions and epidemic intensity during the 1918 influenza pandemic. *Proceedings of the National Academy of Sciences* 2007;104:7582-7587.
21. Koenig KL, Goans RE**, Hatchett RJ,** Mettler FA, Schumacher TA, Noji EK. Medical treatment of radiological casualties: current concepts. *Annals of Emergency Medicine* 2005;45:643-652.
22. Pellmar TC, Rockwell S, **Radiological/Nuclear Threat Countermeasures Working Group.** Priority list of research areas for radiological/nuclear threat countermeasures. *Radiation Research* 2005;163:115-123.
23. Heffernan RT, Pambo B, **Hatchett RJ**, Mavoungou E, Baize S, Leroy E, Yaba P, Lansoud-Soukaté J, Swanepoel R, Ryder RW: Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, northeastern Gabon, 1997. *Journal of Infectious Diseases* 2005;191:964-968.
24. **Hatchett RJ,** Gryglewski RJ, Młochowski J, Zembowicz A, Radziszewski W: Carboxyebselen: A potent and selective inhibitor of endothelial nitric oxide synthase. *Journal of Physiology and Pharmacology* 1994;45:55-67.
25. Zembowicz A, **Hatchett RJ,** Radziszewski W, Gryglewski RJ: Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for catalytic activity of nitric oxide synthase. *Journal of Pharmacology and Experimental Therapeutics* 1993;267:1112-1118.

26. Zembowicz A, **Hatchett RJ,** Jakubowski AM, Gryglewski RJ: Involvement of nitric oxide in the endothelium-dependent relaxation induced by hydrogen peroxide in the rabbit aorta. *British Journal of Pharmacology* 1993;110:151-158.
27. Sugden PH, Fuller SJ, Mynett JR, **Hatchett RJ**, Bogoyevitch MA, Sugden MC: Stimulation of adult rat ventricular myocyte protein synthesis and phosphoinositide hydrolysis by the endothelins. *Biochimica et Biophysica Acta* 1993;1175:327-332.
28. Sekhar KR, **Hatchett RJ,** Shabb JB, Wolfe L, Francis SH, Wells JN, Jastorff B, Butt E, Chakinala MM, Corbin JD: Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate Type Iα, compared to Type Iβ, cGMP-dependent protein kinase. *Molecular Pharmacology* 1992;42:103-108.
29. Fuller SJ, Gaitanaki CJ, **Hatchett RJ**, Sugden PH: Acute a_1-adrenergic stimulation of cardiac protein synthesis may involve increased pH and protein kinase activity. *Biochemical Journal* 1991;273:347-353.

Abstracts

1. **Hatchett RJ.** CDC's pandemic influenza community mitigation guidance: inexact science and the evolution of public health emergency preparedness policy. First International Conference on Infectious Disease Dynamics, 1-3 December 2008.
2. **Hatchett RJ.** Radiation countermeasures: the need for predictive biomarkers. In Ramakrishnan N, Brenner D. Extended abstracts. Workshop: Predicting Individual Radiation Sensitivity: Current and Evolving Technologies. Columbia University, New York, New York, March 17-18, 2008. *Radiation Research* 2008;170:666-675.
3. Maidment B, Benjamin J, Cassatt D, DiCarlo A, Kaminski J, Ramakrishnan N, **Hatchett R.** Radiation/Nuclear Medical Countermeasures Development Program. 12th International Congress of the International Radiation Protection Association, 19-24 October 2008.
4. **Hatchett RJ.** Modeling as a means and barrier to decision making. Institute for Operations Research and the Management Sciences Annual Meeting, 12-15 October 2008.
5. **Hatchett RJ.** Overview of the Needs for Biodosimetry for Acute Events and the Role of Biodosimetry in Current Plans. BioDose 2008, 7-10 September 2008.
6. **Hatchett RJ.** Medical and emergency preparedness for acts of radiological terrorism: the role of the radiation expert. Health Physics 2004;86(suppl):s166.
7. Zembowicz A, **Hatchett RJ,** Radziszewski W, Jakubowski AM, Gryglewski RJ. Ebselen, a novel selective inhibitor of endothelial NO synthase targeting a critical thiol of NOS. *Endothelium* 1993;1(suppl):s12.
8. Zembowicz A, **Hatchett RJ**, Jakubowski AM, Gryglewski RJ. Enhancement of endothelial synthesis of nitric oxide by hydrogen peroxide. *Endothelium* 1993;1(suppl):s66.

Technical Reports and Official Documents

1. National Institutes of Health Strategic Plan and Research Agenda for Medical Countermeasures against Radiological and Nuclear Threats Progress Report: 2005-2011 and Future Research Directions: 2012-2016. Available at http://www.niaid.nih.gov/topics/radnuc/program/Pages/strategicPlanning.aspx.
2. BARDA Strategic Plan 2011-2016. U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority. Washington, D.C.; October 2011. Available at https://www.medicalcountermeasures.gov/Barda/documents/BARDAStrategicPlan9-28--508.pdf
3. The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response. Washington, D.C.; August 2010. Available at http://www.phe.gov/Preparedness/mcm/enterprisereview/Pages/default.aspx.
4. Interim Pre-pandemic Planning Guidance: Community Strategy for Pandemic Influenza Mitigation in the United States: Early, Targeted, Layered Use of Nonpharmaceutical Interventions. Centers for Disease Control and Prevention. Washington, D.C.; February 2007. Available at http://www.pandemicflu.gov/plan/community/community_mitigation.pdf.
5. Ad hoc Radiological and Nuclear Subcommittee Product Development Tools Working Group (**Hatchett R**, Maher C, et al.). Animal Models for Acute Radiation Syndrome: Pertinence to Nuclear Detonation Scenarios. 27 October 2006. For Official Use Only.
6. The National Strategy for Pandemic Influenza Implementation Plan. Homeland Security Council. Washington, D.C.; May 2006. Available at http://www.whitehouse.gov/homeland/nspi_implementation.pdf.
7. Latham D, Pilling D, et al. Defense Science Board 2003 Summer Study on DoD Roles and Missions in Homeland Security, Volume II – a: Supporting Reports. Office of the Undersecretary of Defense for Acquisition, Technology, and Logistics. Washington, D.C.; May, 2004. Available at www.fas.org/irp/agency/dod/dsb/homelandv2.pdf.

8. Koenig KL, **Hatchett RJ,** Alexander G, et al. Work Product of Department of Homeland Security Working Group on Radiological Dispersal Device / Improvised Nuclear Device Working Group: Medical Preparedness and Response Subgroup. December, 2003. Available at www.orau.gov/.../Radiologic_Medical_Countermeasures_051403.pdf.
9. Latham D, Pilling D, et al. Defense Science Board 2003 Summer Study on DoD Roles and Missions in Homeland Security, Volume I. Office of the Undersecretary of Defense for Acquisition, Technology, and Logistics. Washington, D.C.; November, 2003. Available at http://www.fas.org/irp/agency/dod/dsb/index.html.
10. **Hatchett R,** Jarrett D, Pellmar T, et al. Final Report of the Radiological / Nuclear Threat Countermeasures Working Group. Office of Science and Technology Policy. Washington, D.C.; October, 2003. For Official Use Only.

Book Chapters

1. **Hatchett RJ,** Weinstock DM, Goans RE: Radiation accidents and the medical management of acute radiation injury. In Koenig and Schultz's Disaster Medicine: Comprehensive Principles and Practices (2nd), New York City: Cambridge University Press; 2016 (*In Press).*
2. **Hatchett RJ,** Kaminski J, Goans RE: Radiation accidents and the medical management of acute radiation injury. In Koenig and Schultz's Disaster Medicine: Comprehensive Principles and Practices, New York City: Cambridge University Press; 2010. Edited by Kristi L. Koenig, Carl H. Schultz. ISBN 978-0-521-87367-3.
3. **Hatchett RJ,** Kripas CJ: Diagnostic imaging in oncologic emergencies. In Holland-Frei Oncologic Emergencies. Hamilton, Ontario: B.C. Decker; 2002. Edited by Sai-Ching Jim Yeung, Carmen P. Escalante. ISBN 1-55009-171-9.

Other

1. **Hatchett RJ**. Accepting the Challenge of the Past: Polish Medicine in the Period of Transition. *The Pharos* 1995;58(1):34-38.
2. **Hatchett RJ**. Suffering, Literature and the Art of Medicine. *The Pharos* 1992;55(3): 13-17.
3. **Hatchett RJ**. Brave New Worlds: Perspectives on the American Experience of Eugenics. *The Pharos* 1991;54(4):13-18.
4. Book Reviews in *Drama International* (London, UK).
5. Drama Reviews in *The Stage and Television Today* (London, UK).
6. Poems in *The Vanderbilt Review*, *The Southern Humanities Review*, *Negative Capability*, *JAMA*, *Poetry: A Collection of Poetry Written by Medical Students*.

PRESENTATIONS

Congressional Testimony

1. United States House of Representatives Committee on Homeland Security Subcommittee on Emergency Preparedness, Response and Communications, "Taking Measure of Countermeasures (Part I)" (13 April 2011)
2. United States Senate Homeland Security and Governmental Affairs Subcommittees on Oversight of Government Management, the Federal Workforce, and the District of Columbia *and* State, Local, and Private Sector Preparedness and Integration, "Not a Matter of 'If', But of 'When': The Status of U.S. Response Following an RDD Attack" (15 November 2007)
3. United States Senate Commerce Subcommittee on Science, Technology, and Space, "Fighting Bioterrorism: Using America's Scientists and Entrepreneurs to Find Solutions" (5 February 2002)

Invited Presentations/Seminars

1. "BARDA's Perspective on Platforms," National Academy of Sciences Committee on Support to the Department of Defense's Programs to Counter Biological Threats (27 July 2015)
2. "Improvements in Radiation Medical Countermeasures for ARS through BARDA's Funding," Radiation Injury Treatment Network Workshop: The Medical and Organizational Challenges Resulting from a Radiological/Nuclear Emergency (15 July 2015)
3. "Error: The Portal of Discovery," DARPA CHIKV Challenge Scientific Review (12 May 2015)
4. "Introductory Remarks and Overview," Symposium on Accessibility and Development of Tissue Products for Emergency Preparedness (11 May 2015)
5. "Update on Ebola mAb Therapeutics," World Health Organization Consultation on Ebola Therapeutics (6 March 2015)

6. "What Next?" Modeling the Spread and Control of Ebola in West Africa: A Rapid Response Workshop, Georgia Institute of Technology (22 January 2015)
7. "Pathways to the Strategic National Stockpile," Centers for Medical Countermeasures against Radiation Annual Meeting (9 October 2014)
8. "BARDA: Background, Areas of Interest, Partnership Opportunities," Colorado State University Breakfast with BARDA (24 April 2014)
9. "BARDA: Background, Current Initiatives, Partnership Opportunities," U.S. Centers for Disease Prevention and Control National Center for Emerging and Zoonotic Infectious Diseases Division of Vector-Borne Diseases (23 April 2014)
10. "From Bench to Bedside: The Long and Winding Road," Colorado State University Seminar Series Invited Speaker (23 April 2014)
11. "Grand Challenges in Radiation Mitigation and Treatment," Radiation Injury Treatment Network Workshop on the Mitigation and Treatment of Radiation Damage (2 August 2013)
12. "Theme and Variations," Modeling to Support Decision Making, Bill & Melinda Gates Foundation (25 June 2013)
13. "Radiological/Nuclear Incident Scenario," Joint Meeting of the Medical Imaging Drugs Advisory Committee and Oncologic Drugs Advisory Committee, U.S. Food and Drug Administration (3 May 2013)
14. "Influenza Policy Seminar," Georgetown University (24 April 2013)
15. "BARDA's Role in Supporting Medical Product Innovation," HHS Innovation Council (11 February 2013)
16. "Broad Spectrum Antimicrobial (BSA) Program," GTCbio 8th Anti-infectives Partnering and Deal-Making Conference (8 November 2012)
17. "Military and Civilian Shared Priorities in NucRad Readiness," NATO-RTO Symposium on Biological Effects of Radiation Exposure and Countermeasures (10 October 2012)
18. "Longevity and pandemics. Perceptions and misperceptions about risks, spread and impact," 39th General Assembly of the Geneva Association (8 June 2012)
19. "Five Propositions and a Fable about Modeling," Masters Class on Modeling, British Columbia Centre for Disease Control (30 May 2012)
20. "Challenges in Developing Medical Countermeasures for Combined Injury," Armed Forces Radiobiology Research Institute Radiation Combined Injury Symposium: Models, Mechanisms, and Countermeasures (5 April 2012)
21. "Debate: The Value of Modeling during Infectious Disease Outbreaks," International Conference on Emerging Infectious Diseases (12 March 2012)
22. "PAHPA Reauthorization: Improving Our Nation's Preparedness," UPMC Center for Biosecurity Congressional Seminar Series (1 March 2012)
23. "Improving a Path Forward: BARDA's Anthrax MCM Strategy," Public Health Preparedness Summit (23 February 2012)
24. "Preparing for the Perfect 'One Health' Disease: Protecting Human Health against Anthrax," Public Health Preparedness Summit (22 February 2012)
25. "Medical Countermeasure Development: Sustaining Preparedness," Public Health Preparedness Summit (21 February 2012)
26. "Securing Funding to Bridge the Translational Valley of Death," Panel Participant, Phacilitate Vaccine Forum Washington 2012 (30 January 2012)
27. "Where We Are Now and Where We Are Going," Radiation Injury Treatment Network State of the Science Workshop: Radiation Exposure, Medical Countermeasures and Treatment (11 October 2011)
28. "Risk Communication and Vaccines," National Vaccine Plan Stakeholders Meeting (13 September 2011)
29. "Financing Biodefense as a National Security Priority," 2011 Biosecurity Conference: Advancing Bioscience and Global Security (30 June 2011)
30. "Orbis Tertius," Plenary Lecture, Institute on Systems Science and Health (24 May 2011)
31. "Global Health Security: The Health Perspective," American Association for the Advancement of Science Biosecurity Forum (27 October 2010)
32. "National Security Staff Perspective on Value of Medical Intelligence," National Center for Medical Intelligence and National Institute for Mathematical and Biological Synthesis Medical Intelligence Requirements Workshop (19 October 2010)
33. "Medical Countermeasures," Institute of Medicine Forum on Medical and Public Health Preparedness for Catastrophic Events: Meeting on Pandemic and All-Hazards Preparedness Act Reauthorization (7 October 2010)
34. Invited Participant, Washington Ideas Forum Expert Summit: Bending the Health Care Cost Curve (30 September 2010)
35. "White House Views on Biopreparedness," The State of Biopreparedness: Lessons from Leaders, Proposals for Progress (23 September 2010)

36. "Opening Remarks," Invited Presentation as Head of Delegation, U.S. Department of State International Conference on Implementation of the International Health Regulations (19 August 2010)
37. "Decision Making and Decision Support for Public Health Emergencies," Invited Presentation, Virginia Bioinformatics Institute Symposium on Decision and Policy Informatics (13 July 2010)
38. Invited Participant, Pacific Health Summit Meeting on Pandemic Preparedness (22 June 2010)
39. "National Decision Making: What Numbers Did We Need and When?" Invited Presentation, Harvard School of Public Health Center for Communicable Disease Dynamics Annual Meeting (16 June 2010)
40. "Examining Efforts Underway and Existing Gaps," Discussant, Institute of Medicine Forum on Medical and Public Health Preparedness for Catastrophic Events (7 June 2010)
41. "Models of Infectious Disease Agent Study," National Center for Medical Intelligence (11 May 2010)
42. "Transforming the Medical Countermeasure Enterprise," National Defense University Center for the Study of Weapons of Mass Destruction 10th Annual Symposium (5 May 2010)
43. "The Ripple Effect – Referral of Radiation Casualties, Role of the Radiation Injury Treatment Network (RITN), Staff Casualties," Fourth National Emergency Management Summit (3 March 2010)
44. "Pandemic Preparedness and the 2009-H1N1 Flu," American Society of Hematology Annual Meeting, Emergency Preparedness Educational Session (6 December 2009)
45. "The NIAID Radiation Countermeasures Program," National Defense University, Industrial College of the Armed Forces (3 April 2009)
46. "Public Health Preparedness and the Unthinkable: Reflections on Nuclear Terrorism and Pandemic Influenza" Stanford University Center for International Security and Cooperation Science, Technology and Security Seminar Series (3 December 2008)
47. "CDC's Pandemic Influenza Community Mitigation Guidance: Inexact Science and the Evolution of Public Health Emergency Preparedness Policy," Plenary Presentation, First International Conference on Infectious Disease Dynamics (1 December 2008)
48. "Planning and Decision-Making in the Face of Uncertainty," Institut Pasteur 120th Anniversary Conference on Controlling Infectious Diseases: An Agenda for the 21st Century (12 November 2008)
49. "Community Resilience: A Few Concepts," Modeling Social Behavior Workshop (7 November 2008)
50. "Medical Countermeasures for Radiation Combined Injury," Presentation and Participant, 12th Coordination and Planning Meeting of the WHO Radiation Emergency Medical Preparedness Assistance Network Collaborating Centers and Liaison Institutions (16 October 2008)
51. "Modeling as a Means and Barrier to Decision-Making," Panel Participant, Institute for Operations Research and the Management Sciences Annual Meeting (12 October 2008)
52. "The NIAID Radiation Countermeasures Program," University of Pittsburgh Center for Biosecurity (6 October 2008)
53. "Challenges of Replicating Radiation Exposure Scenarios in Animal Models," FDA Workshop on Animal Models for the Treatment of Acute Radiation Syndrome (17 September 2008)
54. "Overview of the Needs for Biodosimetry for Acute Events," BioDose 2008 (8 September 2008)
55. "Radiation/Nuclear Countermeasures Development in the United States," Keynote Address, U.S.-Indo Workshop on Medical Countermeasures for Radiation Injury: Current and Evolving Technologies (17 August 2008)
56. "Engaging Policymakers (What They Really Want from Modelers)," Banff International Research Station for Mathematical Innovation and Discovery Workshop on Mathematical Epidemiology (29 July 2008)
57. "Efficacy of Medical Countermeasures, Including Those Currently Under Development," Institute of Medicine Workshop to Assess Medical Preparedness for a Nuclear Event (26 June 2008)
58. "Thinking Strategically about Radiation Countermeasures Development" Presentation to the National Biodefense Science Board (18 June 2008)
59. "Preparedness and Resiliency in the Framework of Healthy People 2020," Presentation to the Secretary's Advisory Committee on National Health Promotion & Disease Prevention Objectives for 2020 (5 June 2008)
60. "NIAID Briefing on Preparedness for Nuclear Events," Institute of Medicine Committee on Medical Preparedness for a Terrorist Nuclear Attack (21 April 2008)
61. "The MRC and Community Resiliency: A Golden Age for Public Health?" Keynote Address, Medical Reserve Corps National Leadership and Training Conference (11 April 2008)
62. "Radiation Countermeasures Research Program Overview," Briefing to the Government of India Defense Research & Development Organization Radiological Delegation (24 March 2008)
63. "NIAID Radiation Countermeasures Research Program Overview," Presentation to the New York City Department of Health and Mental Hygiene (19 March 2008)
64. "Radiation Countermeasures: The Need for Predictive Biomarkers," NIAID-Columbia University Center for High-Throughput Minimally Invasive Radiation
Biodosimetry Conference on Predicting Individual Radiosensitivity: Current and Evolving Technologies (17 March 2008)

65. "Addressing Gaps in the Medical Countermeasures Marketplace," Presentation to the National Biodefense Science Board (17 December 2007)
66. "Pathway to a Sustainable Medical Countermeasures Enterprise," Briefing to Assistant Secretary for Preparedness and Response RADM Craig Vanderwagen (10 December 2007)
67. "Radiation Countermeasure Research Program Overview," Briefing to White House Office of Science and Technology Policy Staff (7 December 2007)
68. "HHS Radiological / Nuclear Medical Countermeasures Program," Briefing to Senate Homeland Security and Governmental Affairs Committee Staff (6 December 2007)
69. "NIAID Radiation Countermeasures Research Program Overview," Radiation Effects Research Foundation Workshop on Radiation and Age-Associated Immunosenescence (27 November 2007)
70. "Thinking about Medical Countermeasures," Presentation to the Global Health Security Initiative Ministerial Radiological and Chemical Threat Technical Working Groups (30 October 2007)
71. "Radiation Countermeasure Research Program Overview," Briefing to House Science and Technology Committee Investigations and Oversight Subcommittee Staff (17 October 2007)
72. "The Threat," Session Chair, Radiation Injury Treatment Network Education Seminar: Medical and Organizational Challenges Resulting from a Radiological / Nuclear Emergency (25 September 2007)
73. "Medical Surge Capacity Grand Rounds," Discussant, AMA-CDC 2nd National Congress on Health System Readiness: Pandemic Influenza Community Preparedness Planning (18 July 2007)
74. "Use of Modeling to Estimate the Impact of Community-Based Prevention Measures," Plenary Presentation, 2007 Society for Healthcare Epidemiology of America Annual Meeting (17 April 2007)
75. "CDC's Pandemic Influenza Community Mitigation Guidance: Inexact Science and the Evolution of Public Health Emergency Preparedness Policy," Harvard School of Public Health Seminar Series in Infectious Disease Epidemiology (2 April 2007)
76. "Community Mitigation Strategies for Pandemic Influenza," Malcolm Adcock Lectureship, University of Cincinnatti Children's Hospital, (22 March 2007)
77. "Preparing for the Medical Response to a Radiological/Nuclear Mass Casualty Event" Panel Participant, 2007 Public Health Preparedness Summit (22 February 2007)
78. Invited Presentation, NASA-NIH Summit, "The Constellation of NIAID Space-Related Health Research" (8 December 2006)
79. "Effects on Critical Infrastructure and Government," Pandemic Influenza – Past, Present, Future: Communicating Today Based on the Lessons from the 1918-1919 Influenza Pandemic Conference (17 October 2006)
80. "Perspectives on Preparing for Pandemic Influenza," Models of Infectious Disease Agent Study Consultation on Modeling and Policy Making (25 September 2006)
81. "Overview of NIAID Radiation Countermeasures Research Program," Frontiers of Pharmacology and Toxicology Conference (28 August 2006)
82. "Community Planning for Pandemic Influenza: Considerations for DoD," Briefing to the Department of Defense Armed Forces Epidemiology Board (24 August 2006)
83. "Community Planning for Pandemic Influenza: Considerations for DoD," Briefing to the Department of Defense Senior Medical Advisors Council (23 August 2006)
84. "Community Planning for Pandemic Influenza: Considerations for DoD," Briefing to the Department of Defense Avian Influenza Task Force (10 August 2006)
85. "Community Planning for Pandemic Influenza," Keynote Address, Ohio Public Health Epidemiology Conference (2 August 2006)
86. "Community Planning for High-Lethality Pandemic Influenza," Briefing to Department of Homeland Security Assistant Secretary for Policy Stewart Baker (31 July 2006)
87. "Community Planning for Pandemic Influenza," Invited Presentation to the U.S. Food and Drug Administration Center for Drug Evaluation and Research (31 July 2006)
88. "Pandemic Influenza Planning," Luncheon Presentation, 2006 National Citizens Corp Council Meeting (1 June 2006)
89. "Community Planning for High-Lethality Pandemic Influenza," Private Briefing for Homeland Security Advisor Frances Fragos Townsend and White House Senior Staff (30 May 2006)
90. "Community Planning for Pandemic Influenza," Invited Presentation to the Centers for Disease Control and Prevention (8 May 2006)
91. "Community Planning for Pandemic Influenza," Private Briefing for White House Homeland Security Council Deputies Committee (4 May 2006)
92. "Community Planning for Pandemic Influenza," Invited Presentation to the HHS Senior Influenza Policy Group (3 May 2006)

93. "Community Planning for Pandemic Influenza," Modeling of Infectious Disease Agent Study Steering Committee Meeting, (1 May 2006)
94. "The Research Priorities of the New NIH Centers for Medical Countermeasures against Radiation," 11th Coordination and Planning Meeting of the World Health Organization Radiological Emergency Medical Preparedness and Assistance Network Collaborating Centers and Liaison Institutions (27 April 2006)
95. "Community Planning for Pandemic Influenza," Keynote Address, Medical Reserve Corps National Leadership and Training Conference (19 April 2006)
96. "Community Planning for Pandemic Influenza," Private Briefing for Deputy Secretary of Education Raymond Simon (12 April 2006)
97. Panel Participant, University of Pittsburgh Medical Center Center for Biosecurity Hospital Preparedness for Pandemic Influenza Workshop (1 March 2006)
98. "Emergency Preparedness for Radiation Oncologists – Part II," Radiation Oncology Grand Rounds, Duke University Medical Center (21 April 2005)
99. "The V617F JAK2 Mutation and Polycythemia Vera," Medical Oncology Grand Rounds, Duke University Medical Center (20 April 2005)
100. "Emergency Preparedness for Radiation Oncologists – Part I," Radiation Oncology Grand Rounds, Duke University Medical Center (24 March 2005)
101. "Gefitinib, Systems Biology, and the Challenge of Targeted Therapy," Medical Oncology Grand Rounds, Duke University Medical Center (9 March 2005)
102. "Emergency Preparedness for the Hematologist: Radiation Casualties – Consequences and Medical Management," Medical Oncology Grand Rounds, Duke University Medical Center (26 January 2005)
103. "The Need for Public/Private Sector Coordination," Interorganizational Meeting on Radiological/Nuclear Mass Casualty Preparedness (6 December 2004)
104. "Radiological and Nuclear Terrorism: How Real Is the Threat and What Should We Do About It?" Keynote Address, Duke University Radiation Countermeasures Center of Research Excellence Meeting (22 November 2004)
105. "Focused Product Development: A Strategic/Operational Perspective," Blue Ribbon Panel for NIH Strategic Plan and Research Agenda for Medical Countermeasures against Radiological and Nuclear Threats (14 October 2004)
106. "Tough Choices in the Management of Patients with CML," Medical Oncology Grand Rounds, Duke University Medical Center (22 September 2004)
107. "Medical and Emergency Preparedness for Acts of Radiological Terrorism: The Role of the Radiation Expert," Health Physics Society Annual Meeting (13 July 2004)
108. "United States Preparedness and Response Planning for a Smallpox Emergency," Smallpox Biosecurity Conference (26 May 2004)
109. "Radiobiology Research Priorities," Invited Presentation to the NIH Biodefense Research Coordinating Committee (17 February 2004)
110. "Threat Identification: Defining the Threats," National Strategy Forum, Schools: Prudent Preparation for a Catastrophic Terrorism Incident (30 October 2003)
111. "Preparing for Smallpox Bioterror: A US Perspective," Invited Presentation, Substitute for Assistant Secretary Jerome M. Hauer, Smallpox Biosecurity Conference (22 October 2003)
112. "Federal Planning for Isolation, Quarantine, and Disease Containment," Washington Hospital Center Center for Bioterrorism and Emerging Infectious Diseases and Institute for Public Health Emergency Preparedness Conference: SARS, Lessons from Toronto and China (20 October 2003)
113. "CBRN Threats," Guest Lecturer, George Washington University Institute for Crisis, Disaster and Risk Management, EMSE 232: Crisis and Emergency Management (6 October 2003)
114. "Review of HHS Chemical / Biological Defense Program Direction," Invited Presentation, Substitute for Assistant Secretary Jerome M. Hauer, Defense Threat Reduction Agency Threat Reduction Advisory Committee (1 October 2003)
115. "Remarks on TopOff 2," International Nursing Coalition for Mass Casualty Education Summer Conference (22 July 2003)
116. Invited Expert, 2003 National Health Information Infrastructure Annual Conference: Developing a National Action Agenda for NHII, Homeland Security Track
117. "Nursing Response to Mass Casualty Events After 9/11: Research Issues and Needs," Friends of the National Institute of Nursing Research Congressional Breakfast Briefing (17 June 2003)
118. "Influenza and SARS: Implications for Public Health and Homeland Security," Panel Participant, 1st Symposium on Influenza and Cardiovascular Disease: Science, Practice, and Policy (26 April 2003)
119. "Mobilizing Resources: Empowering Professionals," Panel Participant, 2003 Critical Incident Analysis Group Annual Conference (31 March 2003)

120. Induction Speaker, UMDNJ - Robert Wood Johnson Medical School Alpha Omega Alpha Medical Honor Society (4 March 2003)
121. "Burn Centers as a National Resource: The Role of Burn Centers in Homeland Security and Disaster Preparedness," Panel Participant, 2003 American Burn Association National Leadership Conference (26 February 2003)
122. "Panel on BDLS and ADLS," Panel Participant, 2003 EMS State of the Science: A Gathering of Eagles V Conference (21 February 2003)
123. Invited Participant, A Summit on Leadership During Bioterrorism: The Public as an Asset, Not a Problem (3-4 February 2003)
124. "Bioterrorism 101," California District Attorneys Association Winter Workshop (29 January 2003)
125. "A Coalition of Coalitions: Building on Success," Office of the Surgeon General, Developing Training Models and Curricula for the Medical Reserve Corps: Opportunities for Coordination and Collaboration (27 January 2003)
126. "Transportation Issues in Bioterrorism: Considerations for Evacuation and Quarantine," U.S. Department of Transportation Research and Special Programs Administration Workshop (19-20 November 2002)
127. "Healthcare Leadership & Administrative Decision-Making in Response to WMD Incidents," Keynote Address, USPHS Noble Training Center Pilot Course (14 November 2002)
128. "Anthrax and Smallpox: Issues for First Responders," Invited Presentation to the International Association of Fire Chiefs Weapons of Mass Destruction Subcommittee (3 November 2002)
129. "Bioterrorism 101 and Quarantine," National District Attorneys Association Fall Conference (24 September 2002)
130. "The Remote Facility and Public Health Emergency Preparedness," NASA/University of New Mexico Workshop (The Virtual Collaborative Clinic For Health Care Delivery: Bringing Medical Expertise to Remote Patients and Sites in Space and on Earth) (22 August 2002)
131. "Disaster Preparedness for Health Organizations," Panel Participant, ESRI 2002 Users Conference (11 July 2002)
132. "Protecting the Homeland: A Multi-faceted Response to Bioterrorism," Panel Participant, 2002 National Youth Leadership Forum on Medicine (26 June 2002)
133. "Physicians on the Front Line: The Role of a Medical Reserve Corps," Surgical Grand Rounds, University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Campus (22 May 2002)
134. "Connecting the Silos: Capitalizing on Human, Institutional, and Technological Assets to Mitigate Acts of Terrorism," Virginia Bioinformatics Institute (18 March 2002)
135. "Enhanced Preparedness: The Role of a Civilian Medical Reserve," Invited Presentation to the Greater New York Hospital Association Emergency Preparedness Coordinating Council (7 February 2002)
136. "Enhancement of Endothelial Synthesis of Nitric Oxide by Hydrogen Peroxide," Poster Presentation, Third International Meeting: Biology of Nitric Oxide (1993)
137. Invited Poetry Reading, Northeastern Ohio College of Medicine (1994)
138. Invited Poetry Reading, Glascock Poetry Festival (1989)